Deals

Biotech

Summit bets $5B that Akeso’s bispecific will reach cancer peak

Summit Therapeutics is betting $5 billion that Akeso's bispecific antibody will reach new heights in the climb toward new cancer treatments.
Max Bayer Dec 6, 2022 12:50pm

AbbVie connects with HotSpot for $40M cash

Dec 6, 2022 10:50am

Pfizer's hunt for Paxlovid sibling leads to low-profile biotech

Dec 6, 2022 9:35am

Dermata's mid-stage rosacea study sees far-from-rosy results

Dec 5, 2022 11:11am

Rallybio revs up antibody discovery activities in AbCellera pact

Dec 1, 2022 9:30am

BioNTech adds STING to oncology portfolio in €40M Ryvu deal

Nov 30, 2022 8:34am